HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4-oxo-4H-chromene-2-carboxylic acid (2- (2- (4- (2- (6,7- dimethoxy- 3,4- dihydro- 1H- isoquinolin- 2- yl)- ethyl)- phenyl)- 2H- tetrazol- 5- yl)- 4,5- dimethoxyphenyl)amide

structure in first source

Also Known As:

HM-30181; HM30181

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - 4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide: 4
  - Pyrans: 130
    - Benzopyrans: 195
      - 4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - 4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide: 4
    - Isoquinolines: 34
      - 4-oxo-4H-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide: 4

Experts

1.	Köhler, Sebastian C: 1 article (05/2015)
2.	Wiese, Michael: 1 article (05/2015)
3.	Bauer, Florian: 1 article (12/2012)
4.	Chiba, Peter: 1 article (12/2012)
5.	Erker, Thomas: 1 article (12/2012)
6.	Kuntner, Claudia: 1 article (12/2012)
7.	Langer, Oliver: 1 article (12/2012)
8.	Mairinger, Severin: 1 article (12/2012)
9.	Müller, Markus: 1 article (12/2012)
10.	Parveen, Zahida: 1 article (12/2012)

Related Diseases

1.	Neoplasms (Cancer) 02/10/2010 - "These results identify HM30181 as a highly selective and potent inhibitor of MDR1, which in combination with paclitaxel, may provide an orally effective anti-tumor regimen." 02/10/2010 - "Moreover, oral co-administration of paclitaxel and HM30181 showed a tumor-inhibitory strength equal or superior to that of intravenous paclitaxel in the xenograft model in nude mice. " 02/10/2010 - "In this study, we examined the pharmacologic characteristics of HM30181, a newly developed MDR1 inhibitor, and tested its capacity to increase the oral bioavailability and efficacy of paclitaxel, an anti-cancer drug usually given by intravenous injection. "
2.	Breast Neoplasms (Breast Cancer) 05/14/2015 - "HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2)." 12/05/2012 - "This was consistent with HM30181 being at microdoses a dual substrate of Pgp and breast cancer resistance protein (Bcrp). "
3.	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 02/01/2012 - "HM30181 was well tolerated after oral administration within the dose range evaluated, with the exception of the repeated administration of 360 mg, for which gastrointestinal disorders were frequently reported. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Intravenous Injections
2.	Oral Administration